Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment-Reference-Cited by-同舟云学术

Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment

Published:2016-10-12 Issue:7 Volume:23 Page:1690-1697
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Yu Ming-Lung,Huang Chung-Feng,Yeh Ming-Lun,Tsai Pei-Chien,Huang Ching-I.,Hsieh Meng-Hsuan,Hsieh Ming-Yen,Lin Zu-Yau,Chen Shinn-Cherng,Huang Jee-Fu,Dai Chia-Yen,Chuang Wan-Long

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication;Clinical and Molecular Hepatology;2024-07-01

2. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy;Clinical and Molecular Hepatology;2024-07-01

3. A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic;Journal of Microbiology, Immunology and Infection;2023-06

4. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan;Journal of the Formosan Medical Association;2022-08

5. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication;World Journal of Gastroenterology;2022-01-07